Trial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab

Overview

Purpose: To evaluate the efficacy when administering steroid combined with single dose rituximab to eliminate the antibody in acquired hemophilia A patients compared to treatment using steroid with cyclophosphamide. The study will test the hypothesis that steroid combined with small dose rituximab is as effective as steroid combined with cyclophosphamide for FVIII inhibitor eradication in Chinese patients with acquired hemophilia A. Study design Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment

Full Title of Study: “A Prospective, Randomized, Multicenter Clinical Trial of Acquired Haemophilia A With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 9, 2022

Detailed Description

This is a prospective randomized multi-center controlled pilot trial comparing the regimen of steroid with rituximab and steroid with cyclophosphamide to eradicate anti-factor VIII antibodies in Chinese patients with acquired hemophilia A. Patients will be randomized to two regimens: methylprednisolone 0.8mg/kg/day (or equivalent corticosteroid doses) for 3 weeks (then tapering gradually,8 weeks in total) with rituximab (375mg/m2 for one dose) or methylprednisolone 0.8mg/kg/day (or equivalent corticosteroid doses) for 3 weeks (then tapering gradually,8 weeks in total) with cyclophosphamide 2mg/kg/day until inhibitor negative(no longer than five weeks). Patients will be randomized to the treatment cohorts according to the biostatistical methods.

Interventions

  • Drug: Steroid
    • Methylprednisolone 0.8 mg/kg/day (or equivalent corticosteroid doses) for 3 weeks(then tapering gradually, 8 weeks in total)
  • Drug: Rituximab
    • 375mg/m2 for one dose
  • Drug: Cyclophosphamide
    • cyclophosphamide 2 mg/kg/day until inhibitor negative (no longer than five weeks)

Arms, Groups and Cohorts

  • Experimental: Steroid+Rituximab
    • Methylprednisolone 0.8 mg/kg/day (or equivalent corticosteroid doses) for 3 weeks(then tapering gradually, 8 weeks in total)+Rituximab 375mg/m2 for one dose.
  • Active Comparator: Steroid +Cyclophosphamide
    • Methylprednisolone 0.8 mg/kg/day (or equivalent corticosteroid doses) for 3 weeks ( then tapering gradually, 8 weeks in total)+ Cyclophosphamide 2 mg/kg/day until inhibitor negative (no longer than five weeks)

Clinical Trial Outcome Measures

Primary Measures

  • Proportion of inhibitor eradication and time to attain first remission
    • Time Frame: During 18 months
    • The proportion of patients achieving complete remission (CR) defined as titer FVIII inhibitor lower than 0.6 Bethesda unit, factor VIII level> 50% and no bleeding events without bypass treatments for 24 hours and the time to attain first remission will be evaluated.

Secondary Measures

  • Relapse rate and time to relapse
    • Time Frame: During 18 month
    • The proportion of patients who relapse and the time to relapse of each regimen will be measured.

Participating in This Clinical Trial

Inclusion Criteria

  • 18-80 years old – Men or women – Women post-menopausal or with ongoing contraception – Diagnosis of acquired hemophilia A – Patient must be insured – Patient has provided written informed consent prior to enrollment – Patient compliant Exclusion Criteria:

  • Congenital hemophilia – Ongoing treatment with prednisone > 20mg/d (or equivalent corticosteroid doses) more than 1 month – Ongoing treatment with prednisone >0.7mg/kg(or equivalent corticosteroid doses) more than 10 days – Pregnant and breastfeeding women – Allergy to steroid – Immunosuppressive agents treatment within 30 days – Serum transaminase and bilirubin greater than 1.5 times the upper limit of normal value – Hepatitis B surface antigen or hepatitis C antibody or HIV antibody (I + II) or syphilis antibody positive – Patients with diabetes, hypertension, glaucoma, peptic ulcer, herpes zoster, pulmonary infection and so on, who should not be treated with glucocorticoids – Patients with poor compliance – Those who can not take contraceptive measures during the test period – Patient who is considered by the investigator not suitable for clinical study – Thrombocytopenia – Leucocytopenia

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Zhang Lei, MD
  • Collaborator
    • Qilu Hospital of Shandong University
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Zhang Lei, MD, vice Director of Thrombosis and Hemostasis Center – Institute of Hematology & Blood Diseases Hospital, China
  • Overall Official(s)
    • Lei Zhang, MD, Principal Investigator, Blood disease hospital, Chinese academy of medical sciences

References

Collins P, Baudo F, Huth-Kuhne A, Ingerslev J, Kessler CM, Castellano ME, Shima M, St-Louis J, Levesque H. Consensus recommendations for the diagnosis and treatment of acquired hemophilia A. BMC Res Notes. 2010 Jun 7;3:161. doi: 10.1186/1756-0500-3-161.

Collins PW, Hirsch S, Baglin TP, Dolan G, Hanley J, Makris M, Keeling DM, Liesner R, Brown SA, Hay CR; UK Haemophilia Centre Doctors' Organisation. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood. 2007 Mar 1;109(5):1870-7. doi: 10.1182/blood-2006-06-029850. Epub 2006 Oct 17.

Lottenberg R, Kentro TB, Kitchens CS. Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. Arch Intern Med. 1987 Jun;147(6):1077-81. doi: 10.1001/archinte.147.6.1077.

Collins P, Baudo F, Knoebl P, Levesque H, Nemes L, Pellegrini F, Marco P, Tengborn L, Huth-Kuhne A; EACH2 registry collaborators. Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Blood. 2012 Jul 5;120(1):47-55. doi: 10.1182/blood-2012-02-409185. Epub 2012 Apr 18.

Stasi R, Brunetti M, Stipa E, Amadori S. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood. 2004 Jun 15;103(12):4424-8. doi: 10.1182/blood-2003-11-4075. Epub 2004 Mar 2.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.